Creative Medical Technology Holdings, Inc. balance sheet CELZ

Annual Quarterly

As of Jun 30, 2026, Creative Medical Technology Holdings, Inc. had total assets of $9.4 million and total liabilities of $698,595. Total assets were up 32.0% from a year earlier. Stockholders' equity was $8.7 million. Cash and investments were $8.7 million. The current ratio, current assets divided by current liabilities, was 12.91.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Assets
Cash	9 +33.0%	7 +21.3%	6 +71.3%	3 -58.3%	8 -22.4%	11 +10841.4%	0 +10.6%	0 -70.8%	0 +2119.9%	0 -93.8%	0 +221768.0%
Cash and investments	9 +33.0%	7 +21.3%	6 +71.3%	3 -58.3%	8 -22.4%	11 +10841.4%	0 +10.6%	0 -70.8%	0 +2119.9%	0 -93.8%	0 +221768.0%
Receivables	—	—	—	—	0	—	0 -100.0%	0 -41.7%	0 +100.0%	0	—
Inventory	0 +12475.5%	0 -100.0%	0 -66.7%	0 -35.3%	0 -6.2%	0	—	—	—	—	—
Total current assets	9 +36.0%	7 +20.6%	6 -40.3%	10 -45.2%	19 +74.6%	11 +10855.0%	0 +4.0%	0 -70.0%	0 +1595.6%	0 -91.7%	0 +347.3%
Total assets	9 +32.0%	8 +17.1%	7 -37.8%	11 -44.2%	19 +70.3%	11 +1469.9%	1 +35.2%	1 +11.2%	0 +134.9%	0 -37.0%	0 +550.2%
Liabilities and equity
Accounts payable	1 +159.8%	0 -1.0%	0 -13.8%	0 -90.3%	3 +328.9%	1 +117.1%	0 +9.4%	0 -3.3%	0 +39.7%	0 +257.9%	0
Total current liabilities	1 +151.6%	0 -13.1%	0 -11.8%	0 -88.8%	3 +216.2%	1 -97.4%	41 +371.0%	9 +92.4%	4 +83.6%	2 +436.5%	0 +453764.0%
Total liabilities	1 +151.6%	0 -13.1%	0 -11.8%	0 -88.8%	3	—	41 +371.0%	9 +92.4%	4 +83.3%	2 +407.9%	0
Stockholders' equity	9 +26.8%	8 +18.5%	6 -38.7%	10 -34.8%	16 +55.3%	10 +125.7%	-40 -393.1%	-8 -102.1%	-4 -78.6%	-2 -1317.2%	-0 -418.8%
Debt
Long-term debt	—	—	—	—	—	—	—	—	—	0	—
Total debt	—	—	—	—	—	—	—	—	—	0	—
Net cash	—	—	—	—	—	—	—	—	—	-0	—
Ratios
Current ratio	12.91x	25.97x	18.73x	27.65x	5.64x	10.22x	0.00x	0.01x	0.07x	0.01x	0.49x
Return on equity	-69.79%	-79.78%	-86.63%	-51.11%	-63.94%	188.02%	—	—	—	—	—
Return on assets	-64.42%	-76.77%	-82.37%	-49.34%	-52.87%	170.50%	-5,060.81%	-1,598.27%	-2,861.85%	-1,308.96%	-237.53%
Book value per share	1.33	2.03	3.63	7.53	11.27	1.61	-25.90	-0.36	-0.66	-0.02	-0.00

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: CELZ (Nasdaq)
Fiscal year ends: December 31
Incorporated in: NV
Headquarters: Phoenix, AZ
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1187953
Former names: JOLLEY MARKETING INC (until May 13, 2016)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.